Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors
Portfolio Pulse from Vandana Singh
Nkarta Inc (NASDAQ:NKTX) announced updated data from the Phase 1 study of NKX101 for treating acute myeloid leukemia (AML). The results showed a 67% complete response rate in one cohort and a 22% complete response rate in another. However, the company's shares fell by 34.20% following the announcement.
June 27, 2023 | 5:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nkarta's shares fell by 34.20% following the announcement of updated data from the Phase 1 study of NKX101.
The drop in Nkarta's share price is directly linked to the announcement of the updated data from the Phase 1 study of NKX101. Despite some positive results, the market reaction was negative, indicating that investors may have had higher expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100